9-(2-Methoxyaethyl)-6-aminopurin | 5845-34-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 9-(2-Methoxyaethyl)-6-aminopurin
• 英文别名: 9-(2-methoxy-ethyl)-9H-purin-6-ylamine；9-(2-methoxyethyl)-9H-purin-6-amine；9-(2-methoxyethyl)purin-6-amine
• CAS: 5845-34-1
• 化学式: C₈H₁₁N₅O
• mdl: MFCD03446676
• 分子量: 193.208
• InChiKey: UWMBKDNAUNZHFC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.375
• 拓扑面积：
  78.8
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Prodrugs Activated by Rna-Dependent Dna-Polymerases
  申请人：Bertini Ivano

  公开号：US20080300215A1

  公开（公告）日：2008-12-04

  Herein described are prodrugs activated by RNA-dependent DNA-polymerases, such as telomerase and retroviral reverse transcriptases, their use for the treatment of haematological tumours and of blood and blood derivatives from patients affected by retroviral infections, and their use for the preparation of pharmaceutical compositions, to be used for the treatment of solid tumours, of precancerous states and of diseases caused by infection with retroviruses.

  本发明描述了由RNA依赖的DNA聚合酶（如端粒酶和逆转录病毒酶）激活的前药，它们用于治疗血液肿瘤以及受逆转录病毒感染的患者的血液和血液衍生物，并用于制备药物组合物，用于治疗实体肿瘤、癌前状态和由逆转录病毒感染引起的疾病。
• LIVER DELIVERY-BASED ANTIVIRAL PRECURSOR DRUG NUCLEOSIDE CYCLOPHOSPHATE COMPOUND AND USE THEREOF
  申请人：Zhejiang Paloalto Pharmaceutical Technology Co Ltd

  公开号：EP3476854A1

  公开（公告）日：2019-05-01

  Disclosed are a liver specific delivery (LSD)-based antiviral prodrug nucleoside cyclophosphate compound and uses thereof, and in particular, provided are a compound of formula (II), and an isomer, a pharmaceutically acceptable salt, a hydrate and a solvate thereof, and the corresponding pharmaceutical composition. The present invention also provides uses of the present compounds, alone or in combination with other antiviral drugs, in the treatment of the diseases caused by hepatitis B virus (HBV), hepatitis D virus (HDV) and human immunodeficiency virus (HIV).

  本发明公开了一种基于肝脏特异性递送（LSD）的抗病毒原药核苷环磷酸酯化合物及其用途，特别是提供了一种式（II）化合物及其异构体、药学上可接受的盐、水合物和溶液，以及相应的药物组合物。本发明还提供了本发明化合物单独或与其他抗病毒药物联合用于治疗乙型肝炎病毒（HBV）、丁型肝炎病毒（HDV）和人类免疫缺陷病毒（HIV）引起的疾病的用途。
• Biologically active phosphotriester-type compounds
  申请人：Centre National de la Recherch Sientifique

  公开号：US20020037873A1

  公开（公告）日：2002-03-28

  Compounds of formula RS—P(═O) (QR)—Nu where: R is a radical —(CH 2 )n—W—X; X is a radical —C(═Z) (Y) or —S—U; Z is O or S; W is O or S; Q is O or S; Y and U are an alkyl, aryl or saccharide radical which is optionally substituted with, for example, an OH, SH or NH group; n is equal to 1 to 4, preferably 1 or 2; and Nu is a radical consisting of a residue of a biologically active compound or the dephosphorylated residue of a compound which is biologically active when it bears a phosphate or phosphonate group.

  式 RS-P(═O)(QR)-Nu的化合物 其中：R 是基团-(CH 2 )n-W-X；X 是基团-C(═Z) (Y) 或-S-U；Z 是 O 或 S；W 是 O 或 S；Q 是 O 或 S；Y 和 U 是烷基、芳基或糖基，可任选被例如 OH、SH 或 NH 基团取代；n 等于 1 至 4，最好是 1 或 2；Nu 是由生物活性化合物残基或化合物的去磷酸化残基组成的基团，当其带有磷酸或膦酸基时，具有生物活性。
• Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
  申请人：GILEAD SCIENCES, INC.

  公开号：EP2682397B1

  公开（公告）日：2017-04-19
• COMPOSES BIOLOGIQUEMENT ACTIFS DE TYPE PHOSPHOTRIESTERS
  申请人：CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

  公开号：EP0642528B1

  公开（公告）日：1997-01-15